Pasithea Therapeutics (KTTA) Net Income (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Net Income of -$2.9 million for Q1 2026, up 71.62% sequentially from -$10.1 million in Q4 2025, and up 19.47% YoY from -$2.4 million in Q1 2025.
Pasithea Therapeutics (KTTA) Net Income (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Net Income for 6 years, with the latest figure at -$2.9 million in Q1 2026.
- Quarterly Net Income rose 19.47% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.7 million (down 45.03% YoY) and the FY2025 annual result came in at -$20.4 million, down 46.91% from the prior year.
- Net Income grew to -$2.9 million in Q1 2026 per KTTA's latest filing, from -$10.1 million in the prior quarter.
- Over five years, Net Income peaked at $395089.0 in Q3 2022 and troughed at -$10.1 million in Q4 2025.
- A 5-year average of -$2.6 million and a median of -$3.0 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income surged 125.89% in 2022, then slumped 3777.89% in 2024.
- Over 5 years, Net Income stood at -$3.4 million in 2022, then surged by 97.6% to -$81943.0 in 2023, then plunged by 3777.89% to -$3.2 million in 2024, then slumped by 218.19% to -$10.1 million in 2025, then jumped by 71.62% to -$2.9 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$2.9 million, -$10.1 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | -5.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | -10.11 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -3.72 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -3.18 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | -81,943.00 |
| Jun 30, 2023 | -165,146.00 |
| Mar 31, 2023 | -271,869.00 |
| Dec 31, 2022 | -3.42 Mn |
| Sep 30, 2022 | 395,089.00 |
| Jun 30, 2022 | -468,535.00 |
| Mar 31, 2022 | -325,659.00 |
| Dec 31, 2021 | 630,143.00 |
| Sep 30, 2021 | -1.53 Mn |
| Jun 30, 2021 | -727,947.00 |
| Mar 31, 2021 | -549,609.00 |